Get the Stockscreener App
15.54
0.51%
-0.08
After Hours:
15.34
-0.20
-1.29%
Adaptive Biotechnologies Corp stock is traded at $15.54, with a volume of 1.63M.
It is down -0.51% in the last 24 hours and down -14.90% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
See More
Previous Close:
$15.62
Open:
$15.66
24h Volume:
1.63M
Relative Volume:
0.69
Market Cap:
$2.39B
Revenue:
$205.22M
Net Income/Loss:
$-121.24M
P/E Ratio:
-19.09
EPS:
-0.8141
Net Cash Flow:
$-82.81M
1W Performance:
-5.65%
1M Performance:
-14.90%
6M Performance:
+22.75%
1Y Performance:
+105.83%
1-Day Range:
$15.07
$15.81
1-Week Range:
$14.85
$17.98
52-Week Range:
$6.255
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
15.54 | 2.40B | 205.22M | -121.24M | -82.81M | -0.8141 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-30-25 | Initiated | Guggenheim | Buy |
| Jun-18-25 | Initiated | Craig Hallum | Buy |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
Aug Setups: Can Adaptive Biotechnologies Corporation disrupt its industry2025 Support & Resistance & Momentum Based Trading Ideas - baoquankhu1.vn
Allianz Asset Management GmbH Raises Stock Holdings in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) CFO Sells 2,145 Shares of Stock - MarketBeat
ADPT: BTIG Raises Price Target Following Analyst Update | ADPT S - GuruFocus
Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $21.00 - MarketBeat
ADPT: JP Morgan Raises Price Target and Maintains Overweight Rat - GuruFocus
Adaptive Biotechnologies (ADPT) stock swings after earnings as MRD guidance, insider sale draw scrutiny - TechStock²
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2025 Earnings Call Transcript - Insider Monkey
Adeptus Biotechnologies stock price target raised to $22 by BTIG on strong MRD growth By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up on Better-Than-Expected Earnings - MarketBeat
Adeptus Biotechnologies stock price target raised to $22 by BTIG on strong MRD growth - Investing.com UK
Adaptive Biotechnologies Corp (ADPT) Q4 2025 Earnings Call Highl - GuruFocus
Adaptive Biotech (ADPT) Earnings Call Transcript - The Globe and Mail
Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Adaptive Biotechnologies (NASDAQ:ADPT) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
Adaptive Biotechnologies Q4 2025 slides: 55% revenue growth as MRD business expands - Investing.com
Adaptive Biotechnologies (ADPT) Sees Strong Revenue Growth and P - GuruFocus
Earnings call transcript: Adaptive Biotechnologies beats Q4 2025 expectations - Investing.com
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Adaptive Biotechnologies soars after beating Q4 expectations By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies soars after beating Q4 expectations - Investing.com
Adaptive Biotechnologies: Fourth Quarter Financial Highlights - Bitget
Adaptive Biotechnologies: Q4 Earnings Snapshot - KING5.com
Adaptive Biotechnologies earnings beat by $0.09, revenue topped estimates - Investing.com
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Adaptive Biotechnologies (ADPT) falls 24.5% as execs dispose millions of stake - MSN
Biotech Adaptive Biotechnologies lifts 2025 revenue 55%, narrows loss - Stock Titan
Adaptive Biotechnologies earnings on deck: Path to profitability in focus By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies earnings on deck: Path to profitability in focus - Investing.com
Adaptive Biotechnologies CEO Robins sells $2.3 million in stock - Investing.com
Adaptive Biotechnologies CEO Robins sells $2.3 million in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies CSO Robins sells $799k in ADPT stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies CSO Robins sells $799k in ADPT stock - Investing.com
Insider Sell: Harlan Robins Sells 42,788 Shares of Adaptive Biot - GuruFocus
Chad Robins Sells 124,998 Shares of Adaptive Biotechnologies Cor - GuruFocus
Adaptive Biotechnologies Executives Sell Shares - TradingView
299,180 Shares in Adaptive Biotechnologies Corporation $ADPT Acquired by Lisanti Capital Growth LLC - MarketBeat
Adaptive Biotechnologies Reports Strong Revenue Growth Amid Strategic Shift - AD HOC NEWS
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences - The Manila Times
Biotech using immune genetics schedules Feb. and March investor webcasts - stocktitan.net
The Analyst Verdict: Adaptive Biotechnologies In The Eyes Of 4 Experts - Benzinga
Guggenheim Raises Price Target for ADPT to $21, Maintains Buy Ra - GuruFocus
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026 - The Manila Times
First Week of March 20th Options Trading For Adaptive Biotechnologies (ADPT) - Nasdaq
Sumitomo Mitsui Trust Group Inc. Trims Holdings in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Aug Selloffs: Will Adaptive Biotechnologies Corporation stock go up in YEARJuly 2025 Spike Watch & Comprehensive Market Scan Insights - baoquankhu1.vn
Adaptive Biotechnologies Insider Sold Shares Worth $1,411,131, According to a Recent SEC Filing - marketscreener.com
Adaptive Biotechnologies’ Lo Francis sells $1.4m in shares By Investing.com - Investing.com UK
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells 79,590 Shares of Stock - MarketBeat
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):